Publication date: Oct 15, 2024
The recent SARS-CoV-2 pandemic renewed interest toward other non-severe acute respiratory syndrome human coronaviruses. Among these, OC43 is a seasonal human coronavirus widely diffused in the population (90 % seroprevalence in adults) which is responsible for mild respiratory symptoms. As OC43 protective immunity is short lasting, we investigated whether humoral immunity to SARS-CoV-2, induced by vaccination or spontaneous infection, protects against OC43 re-infection at either systemic or mucosal level. A neutralization assay was conducted against “wild type” SARS-CoV-2 lineage B. 1 (EU) and OC43 in VeroE6 cell lines using plasma and saliva samples from 49 subjects who were never infected and received three BNT162b2 RNA vaccine doses (SARS-CoV-2-vaccinated: SV) and from 25 SARS-CoV-2-infected and vaccinated subjects (SIV). The assays were performed right before (T0), fifteen days (T1) and three months (T2) after the third dose administration (SV) or post-infection (SIV). After the third vaccination dose was administered, SARS-CoV-2-specific neutralizing activity (NA) significantly augmented in SV saliva (p
| Concepts | Keywords |
|---|---|
| Bnt162b2 | Cross-reactive immunity |
| Coronaviruses | Human coronaviruses |
| Mild | Mucosal immunity |
| Mucosal | OC43 |
| Vaccinated | SARS-CoV-2 |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | infection |
| disease | MESH | severe acute respiratory syndrome |
| disease | MESH | re-infection |
| disease | IDO | assay |
| disease | IDO | cell |